Prabhu VS, et al. – Researchers here determined 30–day all–cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Findings revealed fewer CDI–associated readmissions among Bezlotoxumab–treated inpatients in comparison to placebo–treated inpatients, notably in participants aged ≥65 years and with severe CDI.